tetano
Editor, Senior Moderator
Clin Microbiol Infect
. 2021 Dec 22;S1198-743X(21)00720-5.
doi: 10.1016/j.cmi.2021.12.012. Online ahead of print.
Persistence of the neutralising antibody response after SARS-CoV-2 infection
Sang-Mu Shim[SUP] 1 [/SUP], Jun-Won Kim[SUP] 2 [/SUP], Sunhee Jung[SUP] 2 [/SUP], Yujung Jung[SUP] 2 [/SUP], Hye-Min Woo[SUP] 2 [/SUP], Jeong-Sun Yang[SUP] 2 [/SUP], Kyung-Chang Kim[SUP] 2 [/SUP], Joo-Yeon Lee[SUP] 3 [/SUP]
Affiliations
Abstract
Objective: Neutralising antibodies are one of the factors to measure individual's immune status for control of infectious diseases. We aimed to confirm the persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralising antibody levels in patients who had recovered from coronavirus disease (COVID-19).
Methods: Plasma donors in South Korea who had completely recovered from SARS-CoV-2 infection had follow-up testing to determine the persistence of neutralising antibodies using a plaque-reduction neutralisation test and ELISA.
Results: Of the 111 participants (20-29 years, 37/111 [33.3%]; 30-39 years, 17/111 [15.3%]; 40-49 years, 23/111 [20.7%]; 50-59, 21/111 [18.9%]; 60-65 years, 13/111 [11.7%]; male, 43/111 [38.7%]; female, 68/111 [61.3%]), 66.1% still had neutralising antibodies approximately 9 months(range 255 to 302 days) after confirmation of the diagnosis.
Conclusions: In this study, we analyzed the titre of neutralising antibodies associated with predicting immune status in individuals with natural infection. Information about the persistence and change in levels of neutralising antibodies against SARS-CoV-2 can be utilised to provide evidence for developing vaccination schedules for individuals with previous infection.
Keywords: COVID-19; ELISA; Plaque-reduction neutralising test; SARS-CoV-2; neutralising antibody.
. 2021 Dec 22;S1198-743X(21)00720-5.
doi: 10.1016/j.cmi.2021.12.012. Online ahead of print.
Persistence of the neutralising antibody response after SARS-CoV-2 infection
Sang-Mu Shim[SUP] 1 [/SUP], Jun-Won Kim[SUP] 2 [/SUP], Sunhee Jung[SUP] 2 [/SUP], Yujung Jung[SUP] 2 [/SUP], Hye-Min Woo[SUP] 2 [/SUP], Jeong-Sun Yang[SUP] 2 [/SUP], Kyung-Chang Kim[SUP] 2 [/SUP], Joo-Yeon Lee[SUP] 3 [/SUP]
Affiliations
- PMID: 34954127
- DOI: 10.1016/j.cmi.2021.12.012
Abstract
Objective: Neutralising antibodies are one of the factors to measure individual's immune status for control of infectious diseases. We aimed to confirm the persistence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) neutralising antibody levels in patients who had recovered from coronavirus disease (COVID-19).
Methods: Plasma donors in South Korea who had completely recovered from SARS-CoV-2 infection had follow-up testing to determine the persistence of neutralising antibodies using a plaque-reduction neutralisation test and ELISA.
Results: Of the 111 participants (20-29 years, 37/111 [33.3%]; 30-39 years, 17/111 [15.3%]; 40-49 years, 23/111 [20.7%]; 50-59, 21/111 [18.9%]; 60-65 years, 13/111 [11.7%]; male, 43/111 [38.7%]; female, 68/111 [61.3%]), 66.1% still had neutralising antibodies approximately 9 months(range 255 to 302 days) after confirmation of the diagnosis.
Conclusions: In this study, we analyzed the titre of neutralising antibodies associated with predicting immune status in individuals with natural infection. Information about the persistence and change in levels of neutralising antibodies against SARS-CoV-2 can be utilised to provide evidence for developing vaccination schedules for individuals with previous infection.
Keywords: COVID-19; ELISA; Plaque-reduction neutralising test; SARS-CoV-2; neutralising antibody.